Clinical Trials on Prostate Ectomy in Australia

Total 292 results

Sanofi

Completed

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Prostate Cancer Metastatic

United Kingdom, Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain
Exelixis

Completed

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

Belgium, France, Italy, Canada, United States, Germany, United Kingdom, Australia, Netherlands, Spain, Austria, Ireland, Puerto Rico, Sweden
Nuvation Bio Inc.

Recruiting

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditions

United States, Australia
University College, London

Recruiting

Prostate Imaging Using MRI +/- Contrast Enhancement (PRIME)

Prostate Cancer

United States, Canada, Spain, Finland, Argentina, Australia, Belgium, Brazil, Denmark, France, Germany, Italy, Netherlands, Singapore, United Kingdom
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

Prostate Cancer | Cancer of the Prostate | Nonmetastatic Castration-Resistant Prostate Cancer

Hong Kong, Canada, China, Germany, Spain, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Australia, Denmark, France, United States, Singapore, Poland, Malaysia, Turkey, Belgium, Argentina, Thailand, Slovakia, Brazil, Finland, Ita... and more
Bayer

Active, not recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Spain, Korea, Republic of, United Kingdom, Australia, Hong Kong, Singapore, Taiwan, Lithuania, Russian Federation, Turkey, France, Israel, Czechia, Italy, Germany, Finland, Austria, Poland, Hungary
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
GlaxoSmithKline

Completed

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Neoplasms, Prostate

United States, Australia, France, Germany, Spain, Bulgaria, Estonia, Italy, Poland, Netherlands, Belgium, United Kingdom, Canada, Denmark, Ukraine, Finland, Latvia, Russian Federation, Greece, Slovenia, Brazil, Mexico, Slovakia, Japan, Puerto... and more
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Achieve Life Sciences

Completed

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

Prostate Cancer

France, United States, Canada, Australia, Hungary, Czech Republic, Russian Federation, United Kingdom
GlaxoSmithKline

Terminated

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Solid Tumours

United States, Spain, Australia, United Kingdom
Boston Scientific Corporation

Recruiting

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy (SABRE)

Prostate Cancer

Australia, Spain, United States, United Kingdom, Germany, Ireland, France, Italy, Switzerland
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (CheckMate 650)

Prostate Cancer

Poland, United States, Australia, Austria, Canada, Denmark, France, Germany, Italy, Spain
Ontario Clinical Oncology Group (OCOG)
Canadian Institutes of Health Research (CIHR); Trans Tasman Radiation Oncology...

Completed

PROFIT - Prostate Fractionated Irradiation Trial

Prostate Cancer

Canada, Australia, France
University Ghent
University Hospital, Geneva

Active, not recruiting

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Metastatic | Oligometastatic Cancer

Norway, Spain, Belgium, Switzerland, Australia, Italy
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
Impact Therapeutics, Inc.

Completed

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Primary Peritoneal Cancer | Advanced Solid Tumours

Australia
Bayer

Completed

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)

Bone Metastases | Hormone Refractory Prostate Cancer

Italy, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
SOTIO a.s.

Completed

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)

Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
Hoffmann-La Roche

Completed

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Millennium Pharmaceuticals, Inc.

Completed

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Prostate Cancer

France, United States, Belgium, Spain, Australia, Canada, Netherlands, Italy, Poland, Czechia, Estonia, Finland, Hungary, Greece
Abbott

Completed

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Prostate Cancer

United States, Canada, France, Spain, Belgium, Australia, United Kingdom, Italy, Sweden, South Africa, Netherlands, Ireland, Germany, Austria, New Zealand, Greece, Poland, Switzerland
Astellas Pharma Europe Ltd.
Medivation, Inc.

Completed

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (PREMISE)

Metastatic Castration Resistant Prostate Cancer

Czechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
European Organisation for Research and Treatment...

Completed

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

Belgium, Poland, Italy, Austria, France, Denmark, Netherlands, United Kingdom, Israel, Spain, Portugal
Bristol-Myers Squibb

Completed

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Prostate Cancer

United States, France, Mexico, Sweden, Canada, Australia, Italy, Colombia, Denmark, Argentina, Chile, Spain, Germany, Puerto Rico, United Kingdom, Czech Republic, Romania, Norway, Poland, Netherlands, Brazil, Hungary, Turkey, Greece
Viralytics

Completed

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) (PSX-X04)

Melanoma | Breast Cancer | Prostate Cancer

Australia
GP-Pharm

Completed

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

Prostate Cancer

United States, Austria, Czech Republic, Germany, Hungary, Italy, Slovakia, Spain, United Kingdom
Bristol-Myers Squibb

Completed

Study of Immunotherapy to Treat Advanced Prostate Cancer

Prostate Cancer

United States, Argentina, Italy, Mexico, Spain, United Kingdom, Netherlands, Australia, Colombia, Belgium, Austria, Denmark, Puerto Rico, France, Israel, Peru, Romania, Russian Federation, Hungary, Brazil, Germany, Czech Republic, C... and more
Novartis Pharmaceuticals

Completed

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

Prostate Cancer

Saudi Arabia, Taiwan, Korea, Republic of, Lebanon, Brazil, China, New Zealand, Australia, Thailand, Kuwait
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Prostate Cancer

Australia, United States, Chile, Spain, France, Italy, United Kingdom, Germany, Netherlands
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C)

Prostate Cancer

Sweden, United States, Brazil, France, Peru, Spain, United Kingdom, Germany, Poland, Romania, Finland, Canada, Argentina, Australia, South Africa, Czech Republic, India, Netherlands, Italy, Switzerland, Korea, Republic of, Hungary, ... and more
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, Germany, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway, Czechia, Finland, Hong Kong, Netherlands, Poland, Spain, Sweden, Turkey, Denmark, Hungary, Italy, United Kingdom, ... and more
Advanced Medical Diagnostics s.a.

Terminated

Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning (PHSTT-01)

Prostate Cancer

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Russian Federation, Spain, Switzerland, Turkey, United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
University of Sydney
Memorial Sloan Kettering Cancer Center; Bayer; Canadian Cancer Trials Group; Australian... and other collaborators

Active, not recruiting

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

Prostate Cancer

United States, Canada, Australia, United Kingdom, New Zealand, Ireland
Corvus Pharmaceuticals, Inc.
Genentech, Inc.

Completed

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Renal Cell Cancer | Metastatic Castration Resistant Prostate Cancer

United States, Canada, Australia
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, Austria, United Kingdom
RDC Clinical Pty Ltd

Recruiting

Comparison of 2 Extracts of Saw Palmetto Versus Placebo on BPH Symptoms

Benign Prostatic Hyperplasia

Australia
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

Prostate Cancer

Canada, United States, Spain, Australia, Denmark, Korea, Republic of, Belgium, Singapore, Finland, Netherlands, France, Austria, Germany, Israel, United Kingdom, Italy, Japan, Lithuania, Poland, Russian Federation, Slovakia, Sweden
Celgene

Completed

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Prostate Cancer

United States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
Clarity Pharmaceuticals Ltd

Completed

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER) (PROPELLER)

Prostatic Neoplasms

Australia
ProVerum Medical

Completed

The ProVerum First in Man PROVE Study

Benign Prostatic Hyperplasia

Australia
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Metastatic Castration-resistant Prostate Cancer

United States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
AstraZeneca

Completed

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Prostate Cancer

Sweden, United States, Australia, France, United Kingdom, Poland, Finland, Netherlands, Norway, Belgium, Canada, Indonesia, Denmark, Switzerland
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, France, United States, Australia, Brazil, Germany, Taiwan, Denmark, China, Netherlands, Japan, Canada, Finland, Italy, Hungary, Portugal, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
Myovant Sciences GmbH

Completed

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO)

Prostate Cancer

United States, Germany, Spain, New Zealand, Brazil, Belgium, Australia, Austria, Canada, China, Denmark, Finland, France, Italy, Japan, Korea, Republic of, Netherlands, Poland, Slovakia, Sweden, Taiwan, United Kingdom
LTN PHARMACEUTICALS, INC.

Terminated

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV)

Prostate Cancer

United States, France, Australia, Canada, Spain, United Kingdom, Italy, Belgium
AstraZeneca

Active, not recruiting

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Breast | Prostate | Ovarian | Pancreatic | Advanced Tumours

Sweden, Spain, Israel, Australia, Germany
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Russian Federation, United Kingdom, Germany, China, Hungary, Poland, Finland, Netherlands, Mexico, Hong Kong, Australia, Belgium, Canada, Denmark, Portugal, South Africa, Korea... and more

Clinical Trials on Prostate Ectomy in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations